NCT00659997

Brief Summary

Field epidemiological studies undertaken during 2005 in four village locations in Northern Unguja, Zanzibar examined mothers and their pre-school aged children for helminth infections. The prevalence of Ascaris lumbricoides was found to have remained relatively high despite community-wide treatment with the mass administration of Albendazole (a WHO recommended de-wormer) in coordination with community vitamin A supplementation. One hypothesis for this is that the children and mothers had Ascaris infections more tolerant to Albendazole that subsequently failed to clear. It is necessary to compare the present drug efficiency of Albendazole (first-line de-wormer) with Levamisole (second-line de-wormer) on STH infections such patients a case-control setting to shed light on the putative resistance of local Ascaris/Trichuris to albendazole. In so doing, this should clarify whether there is resistance developing towards Albendazole and have possible implications for introducing combination therapies of Levamisole and Albendazole for first line de-worming mothers and their children in the future.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for phase_4

Timeline
Completed

Started Jun 2006

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2006

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2006

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2007

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

April 10, 2008

Completed
7 days until next milestone

First Posted

Study publicly available on registry

April 17, 2008

Completed
Last Updated

April 17, 2008

Status Verified

April 1, 2008

Enrollment Period

3 months

First QC Date

April 10, 2008

Last Update Submit

April 15, 2008

Conditions

Keywords

AscariasisTrichuriasisDrug resistance

Outcome Measures

Primary Outcomes (1)

  • Clearance of STH faecal eggs in patient stool

    18 days

Study Arms (2)

1

ACTIVE COMPARATOR

1 Individuals treated with Albendazole

Drug: Albendazole

2

ACTIVE COMPARATOR

Individuals treated with Levamisole

Drug: Levamisole

Interventions

Single oral dose of 400mg

1

Single oral dose of 2.5mg/kg

2

Eligibility Criteria

Age1 Year - 45 Years
Sexfemale
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Presently with soil-transmitted helminthiasis

You may not qualify if:

  • absence of soil-transmitted helminthiasis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Helminth Control Laboratory Unguja

Stone Town, Tanzania

Location

Related Publications (1)

  • Stothard JR, Imison E, French MD, Sousa-Figueiredo JC, Khamis IS, Rollinson D. Soil-transmitted helminthiasis among mothers and their pre-school children on Unguja Island, Zanzibar with emphasis upon ascariasis. Parasitology. 2008 Oct;135(12):1447-55. doi: 10.1017/S0031182008004836. Epub 2008 Sep 8.

MeSH Terms

Conditions

AscariasisTrichuriasis

Interventions

AlbendazoleLevamisole

Condition Hierarchy (Ancestors)

Ascaridida InfectionsSecernentea InfectionsNematode InfectionsHelminthiasisParasitic DiseasesInfectionsEnoplida InfectionsAdenophorea Infections

Intervention Hierarchy (Ancestors)

CarbamatesAcids, AcyclicCarboxylic AcidsOrganic ChemicalsBenzimidazolesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic CompoundsThiazolesSulfur CompoundsImidazolesAzolesHeterocyclic Compounds, 1-Ring

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER GOV

Study Record Dates

First Submitted

April 10, 2008

First Posted

April 17, 2008

Study Start

June 1, 2006

Primary Completion

September 1, 2006

Study Completion

September 1, 2007

Last Updated

April 17, 2008

Record last verified: 2008-04

Locations